- Home
- MEGI vs URGN Comparison
MEGI vs URGN Comparison
Compare MEGI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGI
- URGN
- Stock Information
- Founded
- MEGI 2021
- URGN 2004
- Country
- MEGI United States
- URGN United States
- Employees
- MEGI N/A
- URGN N/A
- Industry
- MEGI Investment Managers
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MEGI Finance
- URGN Health Care
- Exchange
- MEGI Nasdaq
- URGN Nasdaq
- Market Cap
- MEGI 774.5M
- URGN 830.4M
- IPO Year
- MEGI N/A
- URGN 2017
- Fundamental
- Price
- MEGI $14.82
- URGN $19.02
- Analyst Decision
- MEGI
- URGN Strong Buy
- Analyst Count
- MEGI 0
- URGN 8
- Target Price
- MEGI N/A
- URGN $28.50
- AVG Volume (30 Days)
- MEGI 178.0K
- URGN 1.0M
- Earning Date
- MEGI 01-01-0001
- URGN 11-11-2025
- Dividend Yield
- MEGI 11.40%
- URGN N/A
- EPS Growth
- MEGI N/A
- URGN N/A
- EPS
- MEGI N/A
- URGN N/A
- Revenue
- MEGI N/A
- URGN $94,238,000.00
- Revenue This Year
- MEGI N/A
- URGN $39.63
- Revenue Next Year
- MEGI N/A
- URGN $111.49
- P/E Ratio
- MEGI N/A
- URGN N/A
- Revenue Growth
- MEGI N/A
- URGN 10.85
- 52 Week Low
- MEGI $10.63
- URGN $3.42
- 52 Week High
- MEGI $14.89
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- MEGI 53.99
- URGN 58.36
- Support Level
- MEGI $14.76
- URGN $16.95
- Resistance Level
- MEGI $15.04
- URGN $18.57
- Average True Range (ATR)
- MEGI 0.21
- URGN 0.96
- MACD
- MEGI -0.01
- URGN 0.18
- Stochastic Oscillator
- MEGI 48.94
- URGN 93.77
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.